The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19)

References

• Zhu N, Zhang D, Wang W, et al. China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi:10.3390/v12020135
   PubMed Web of Science ®Google Scholar
• Shimizu K. 2019-nCoV, fake news, and racism. Lancet. 2020;395(10225):685–686. doi:10.1016/S0140-6736(20)30357-3
   PubMed Web of Science ®Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316
   PubMed Web of Science ®Google Scholar
• Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Revista Panamericana de Salud Pública. 2020;44:e40. doi:10.26633/RPSP.2020.40
   PubMed Web of Science ®Google Scholar
• Zhu R-F, Gao R-L, Robert S-H, Gao J-P, Yang S-G, Zhu C. Systematic review of the registered clinical trials of coronavirus diseases 2019 (COVID-19). medRxiv. 2020.
   Google Scholar
• Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.
   Web of Science ®Google Scholar
• Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001
   PubMed Web of Science ®Google Scholar
• Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292.
   PubMed Web of Science ®Google Scholar
• Arafah A, Ali S, Yatoo AM, Ali MN, Rehman MU. S1 subunit and host proteases as potential therapeutic avenues for the treatment of COVID-19. Arch Med Res. 2020. doi:10.1016/j.arcmed.2020.05.013
   PubMed Web of Science ®Google Scholar
• Manhas S, Anjali A, Mansoor S, et al. Covid-19 pandemic and current medical interventions. Arch Med Res. 2020;51(6):473–481. doi:10.1016/j.arcmed.2020.05.007
   PubMed Web of Science ®Google Scholar
• Bolcato G, Bissaro M, Pavan M, Sturlese M, Moro S Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors Lopinavir, Ritonavir, and Nelfinavir. 2020.
   Google Scholar
• Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6).
   Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1–e5. doi:10.1016/j.jinf.2020.03.002
   PubMed Web of Science ®Google Scholar
• Belhadi D, Peiffer-Smadja N, Yazdanpanah Y, Mentré F, Laouénan C. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv. 2020.
   Google Scholar
• Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6).
   Web of Science ®Google Scholar
• Lim J, Jeon S, Shin HY, et al. The author’s response: case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(7).
   Web of Science ®Google Scholar
• Zhang T, He Y, Xu W, Ma A, Yang Y, Xu K-F. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): a rapid response to urgent need. Sci China Life Sci. 2020;1–3. doi:10.1007/s11427-020-1662-x
   PubMed Web of Science ®Google Scholar
• Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus – a possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020;92(6):556–563. doi:10.1002/jmv.25729
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18. doi:10.1128/mBio.00221-18
   PubMed Web of Science ®Google Scholar
• Karimi A, Rafiei Tabatabaei S, Rajabnejad M, et al. An algorithmic approach to diagnosis and treatment of coronavirus disease 2019 (COVID-19) in children: Iranian expert’s consensus statement. Arch Pediatr Infect Dis. 2020;8(2):e102400.
   Web of Science ®Google Scholar
• Nicastri E, Petrosillo N, Bartoli TA, et al. National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020;12(1). doi:10.4081/idr.2020.8543
   PubMed Web of Science ®Google Scholar
• Goldhill DH, Te Velthuis AJ, Fletcher RA, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci. 2018;115(45):11613–11618. doi:10.1073/pnas.1811345115
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. doi:10.1016/j.eng.2020.03.007
   Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.01012
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020.
   Google Scholar
• Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. doi:10.1016/j.ijantimicag.2020.105938
   PubMed Web of Science ®Google Scholar
• Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;104762.
   PubMed Web of Science ®Google Scholar
• Frisk-Holmberg M, Bergqvist Y, Englund U. Chloroquine intoxication. Br J Clin Pharmacol. 1983;15(4):502. doi:10.1111/j.1365-2125.1983.tb01540.x
   PubMed Web of Science ®Google Scholar
• Ahmad A, Rehman MU, Ahmad P, Alkharfy KM. Covid-19 and thymoquinone: connecting the dots. Phytother Res. 2020. doi:10.1002/ptr.6793
   Web of Science ®Google Scholar
• Huang L, Shi Y, Gong B, et al. Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19. medRxiv. 2020.
   Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5
   PubMed Web of Science ®Google Scholar
• Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv Preprint arXiv:200300751. 2020.
   Google Scholar
• Sun -S-S. Pathogen infection recovery probability (PIRP) versus proinflammatory anti-pathogen species (PIAPS) levels: modelling and therapeutic strategies. arXiv Preprint arXiv:200305507. 2020.
   Google Scholar
• Liu Q, Zhou Y-H, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10. doi:10.1038/cmi.2015.74
   PubMed Web of Science ®Google Scholar
• Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020.
   Web of Science ®Google Scholar
• Shang J, Du R, Lu Q, et al. The treatment and outcomes of patients with COVID-19 in Hubei, China: a multi-centered, retrospective, observational study. 2020.
   Google Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385. doi:10.1080/22221751.2020.1729069
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020.
   Web of Science ®Google Scholar
• Ahmad A, Rehman M, Alkharfy K. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections. Eur Rev Med Pharmacol Sci. 2020;24(7):4030–4034.
   PubMed Web of Science ®Google Scholar
• Ren J, Zhang A-H, Wang X-J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 2020;155:104743. doi:10.1016/j.phrs.2020.104743
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo JJ, Healy DP, Zhan S. Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: a meta-analysis. Pharm Pract. 2007;5(1):1–9.
   PubMedGoogle Scholar
• Onishi S, Mori T, Kanbara H, et al. Green tea catechins adsorbed on the murine pharyngeal mucosa reduce influenza A virus infection. J Funct Foods. 2020;68:103894. doi:10.1016/j.jff.2020.103894
   Web of Science ®Google Scholar
• Chen C-N, Lin CP, Huang -K-K, et al. Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3, 3ʹ-digallate (TF3). Evid Based Complement Alternat Med. 2005;2(2):209–215. doi:10.1093/ecam/neh081
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Mukai T, Furukawa S, Ohori H. Inhibitory effects of epigallocatechin gallate on the propagation of bovine coronavirus in Madin‐Darby bovine kidney cells. Anim Sci J. 2005;76(5):507–512. doi:10.1111/j.1740-0929.2005.00297.x
   Google Scholar
• Lee YH, Jang YH, Kim Y-S, Kim J, Seong BL. Evaluation of green tea extract as a safe personal hygiene against viral infections. J Biol Eng. 2018;12(1):1. doi:10.1186/s13036-017-0092-1
   PubMed Web of Science ®Google Scholar
• Mahmood MS, Mártinez JL, Aslam A, et al. Antiviral effects of green tea (Camellia sinensis) against pathogenic viruses in human and animals (a mini-review). Afr J Tradit Complement Altern Med. 2016;13(2):176–184. doi:10.4314/ajtcam.v13i2.21
   PubMedGoogle Scholar
• Okada F. Antiviral effects of tea catechins and black tea theaflavins on plant viruses. JARQ. 1978;12:27–32.
   Google Scholar
• Xu J, Xu Z, Zheng W. A review of the antiviral role of green tea catechins. Molecules. 2017;22(8):1337.
   PubMed Web of Science ®Google Scholar
• Song J-M, Lee K-H, Seong B-L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005;68(2):66–74. doi:10.1016/j.antiviral.2005.06.010
   PubMed Web of Science ®Google Scholar
• Imanishi N, Tuji Y, Katada Y, et al. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol. 2002;46(7):491–494. doi:10.1111/j.1348-0421.2002.tb02724.x
   PubMed Web of Science ®Google Scholar
• Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:10.1016/j.phrs.2020.104761
   PubMed Web of Science ®Google Scholar
• Sun N, Wong WL, Guo J. Prediction of potential 3CLpro-targeting anti-SARS-CoV-2 compounds from Chinese medicine. 2020.
   Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228. doi:10.14336/AD.2020.0228
   PubMed Web of Science ®Google Scholar
• Chen J, Hu C, Chen L, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering. 2020. doi:10.1016/j.eng.2020.02.006
   Web of Science ®Google Scholar
• Orleans L, Is Vice H, Manchikanti L. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23:E71–E83.
   PubMed Web of Science ®Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90. doi:10.1093/infdis/jiu396
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. doi:10.1172/JCI138003
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020.
   Web of Science ®Google Scholar
• Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. doi:10.1016/S1473-3099(20)30141-9
   PubMed Web of Science ®Google Scholar
• Kuhn JH, Radoshitzky SR, Li W, Wong SK, Choe H, Farzan M. The SARS coronavirus receptor ACE 2 A potential target for antiviral therapy. New Concepts Antivir Ther. 2006;397–418.
   Google Scholar
• Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020;526(1):165–169. doi:10.1016/j.bbrc.2020.03.047
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi:10.1126/science.abb2507
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. doi:10.1016/j.cell.2020.04.004
   PubMed Web of Science ®Google Scholar
• Ton A-T, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inform. 2020;39(8):2000028. doi:10.1002/minf.202000028
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
   PubMed Web of Science ®Google Scholar
• Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano. 2020.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, Liu S, Zheng B-J JS. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
   PubMed Web of Science ®Google Scholar
• Lung J, Lin YS, Yang YH, et al. The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase. J Med Virol. 2020;92(6):693–697. doi:10.1002/jmv.25761
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Báez-Santos YM, John SES, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38. doi:10.1016/j.antiviral.2014.12.015
   PubMed Web of Science ®Google Scholar
• Shin YW, Chang K-H, Hong G-W, et al. Selection of vaccinia virus-neutralizing antibody from a phage-display human-antibody library. J Microbiol Biotechnol. 2019;29(4):651–657.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for COVID-19. EXCLI J. 2020;19:528.
   PubMed Web of Science ®Google Scholar
• Chowdhury UF, Shohan MUS, Hoque KI, Beg MA, Siam MKS, Moni MA. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2. bioRxiv. 2020.
   Google Scholar
• Weiss C, Carriere M, Fusco L, et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano. 2020;14(6):6383–6406. doi:10.1021/acsnano.0c03697
   PubMed Web of Science ®Google Scholar
• Kumar S, Zhi K, Mukherji A, Gerth K. Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19. Viruses. 2020;12(5):486. doi:10.3390/v12050486
   PubMed Web of Science ®Google Scholar
• Shaikhpoor M, Ahangari G, Sadeghizadeh M, Khosravi A, Derakhshani Deilami G. Significant changes in D2-like dopamine gene receptors expression associated with non-small-cell lung cancer: could it be of potential use in the design of future therapeutic strategies? Curr Cancer Ther Rev. 2012;8(4):304–310.
   Google Scholar
• Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother. 2002;51(9):467–482. doi:10.1007/s00262-002-0300-8
   PubMed Web of Science ®Google Scholar
• Sheikhpour M, Sadeghizadeh M, Yazdian F, et al. Co-administration of curcumin and bromocriptine nano-liposomes for induction of apoptosis in lung cancer cells. Iran Biomed J. 2020;24(1):24. doi:10.29252/ibj.24.1.24
   PubMedGoogle Scholar
• Sheikhpour M, Ahangari G, Sadeghizadeh M, Deezagi A. A novel report of apoptosis in human lung carcinoma cells using selective agonist of D2-like dopamine receptors: a new approach for the treatment of human non-small cell lung cancer. Int J Immunopathol Pharmacol. 2013;26(2):393–402. doi:10.1177/039463201302600212
   PubMed Web of Science ®Google Scholar
• Rein T. Is autophagy involved in the diverse effects of antidepressants? Cells. 2019;8(1):44. doi:10.3390/cells8010044
   PubMed Web of Science ®Google Scholar
• Read MC. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do (WHO, Feb 21 2013). World Health. 2013;4:22.
   Google Scholar
• Szałach ŁP, Lisowska KA, Cubała WJ. The influence of antidepressants on the immune system. Arch Immunol Ther Exp (Warsz). 2019;67(3):143–151. doi:10.1007/s00005-019-00543-8
   PubMed Web of Science ®Google Scholar
• Di Rosso ME, Palumbo ML, Genaro AM. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res. 2016;109:101–107. doi:10.1016/j.phrs.2015.11.021
   PubMed Web of Science ®Google Scholar
• Zumla A, Azhar EI, Arabi Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Elsevier. 2015;71–74.
   Google Scholar
• Yaseen AZEIA, Brian ABAMR, Eskild M, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. 2015.
   Google Scholar
• Jiang HY, Deng M, Zhang YH, Chen HZ, Chen Q, Ruan B. Specific serotonin reuptake inhibitors prevent interferon-α–induced depression in patients with hepatitis C: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12(9):1452–60. e3. doi:10.1016/j.cgh.2013.04.035
   PubMed Web of Science ®Google Scholar
• Ris DR. COVID-19, interferons, and depression: a commentary. Psychiatry Res. 2020;113198.
   PubMed Web of Science ®Google Scholar
• Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy. 1987;7(1):1–15. doi:10.1002/j.1875-9114.1987.tb03496.x
   PubMed Web of Science ®Google Scholar
• Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother. 2012;56(9):4838–4844. doi:10.1128/AAC.00983-12
   PubMed Web of Science ®Google Scholar
• Peng L, Gu L, Li B, Hertz L. Fluoxetine and all other SSRIs are 5-HT2B agonists-importance for their therapeutic effects. Curr Neuropharmacol. 2014;12(4):365–379. doi:10.2174/1570159X12666140828221720
   PubMed Web of Science ®Google Scholar
• Stanley SA, Barczak AK, Silvis MR, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 2014;10(2):e1003946. doi:10.1371/journal.ppat.1003946
   PubMed Web of Science ®Google Scholar
• Ulferts R, van der Linden L, Thibaut HJ, et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother. 2013;57(4):1952–1956. doi:10.1128/AAC.02084-12
   PubMed Web of Science ®Google Scholar
• Organization WH. Mental health and psychosocial considerations during the COVID-19 outbreak, 18 March 2020. World Health Organization; 2020.
   Google Scholar